ABI is in the process of developing an innovative, technology-driven treatment to address metabolism related diseases such as T1 and T2 diabetes using a pulsatile insulin infusion therapy that mimics the normal pancreas’ functions. Variations of the protocol have already been commercialized in the U.S.
by other entities unrelated to ABI. These procedures have been developed over a period of twenty-seven years and during this time frame, fourteen clinical studies and sixty-five supportive studies and publications have been completed by various sources.
Thus far, the therapy has been a highly safe and effective tool for diabetes management, by addressing the underlying metabolic causes of diabetes in order to halt the progression of and in some cases reverse complications of the disease. It is uniformly effective for treatment of both Type 1 and Type 2 diabetes and has shown to be effective in even the most impaired patients. For the past few years, our Medical Division has sponsored demonstration clinical operations in Taiwan and Hong Kong, and is planning to introduce its own proprietary treatment protocol in Greater China, and eventually in other Asian countries.